Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’

On March 29, Insilico Medicine announced a drug discovery deal with Eli Lilly that gives the Big Pharma firm an exclusive worldwide license to a portfolio of preclinical oral therapeutics. The collaboration also  sets up joint R&D programs across a range of therapeutic areas. Under the terms of the deal, Insilico is eligible for a… The post Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’ appeared first on Drug Discovery and Development.

Continue reading →